VYZULTA Drug Patent Profile

Which patents cover Vyzulta, and when can generic versions of Vyzulta launch?

Vyzulta is a drug marketed by Bausch And Lomb and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-three patent family members in thirty-eight countries.

The generic ingredient in VYZULTA is latanoprostene bunod. Two suppliers are listed for this compound. Additional details are available on the latanoprostene bunod profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vyzulta

A generic version of VYZULTA was approved as latanoprostene bunod by GLAND on April 29^th, 2025.

Summary for VYZULTA

International Patents:	53
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	36
Clinical Trials:	2
Patent Applications:	223
Drug Prices:	Drug price information for VYZULTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VYZULTA
What excipients (inactive ingredients) are in VYZULTA?	VYZULTA excipients list
DailyMed Link:	VYZULTA at DailyMed

See drug prices for VYZULTA

Recent Clinical Trials for VYZULTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Icahn School of Medicine at Mount Sinai	Phase 4
University of California, San Diego	N/A
Bausch & Lomb Incorporated	N/A

See all VYZULTA clinical trials

Paragraph IV (Patent) Challenges for VYZULTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VYZULTA	Ophthalmic Solution	latanoprostene bunod	0.024%	207795	1	2022-03-31

US Patents and Regulatory Information for VYZULTA

VYZULTA is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb	VYZULTA	latanoprostene bunod	SOLUTION/DROPS;OPHTHALMIC	207795-001	Nov 2, 2017	AB	RX	Yes	Yes				Y
Bausch And Lomb	VYZULTA	latanoprostene bunod	SOLUTION/DROPS;OPHTHALMIC	207795-001	Nov 2, 2017	AB	RX	Yes	Yes			Y	Y
Bausch And Lomb	VYZULTA	latanoprostene bunod	SOLUTION/DROPS;OPHTHALMIC	207795-001	Nov 2, 2017	AB	RX	Yes	Yes			Y
Bausch And Lomb	VYZULTA	latanoprostene bunod	SOLUTION/DROPS;OPHTHALMIC	207795-001	Nov 2, 2017	AB	RX	Yes	Yes			Y	Y

Expired US Patents for VYZULTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch And Lomb	VYZULTA	latanoprostene bunod	SOLUTION/DROPS;OPHTHALMIC	207795-001	Nov 2, 2017
Bausch And Lomb	VYZULTA	latanoprostene bunod	SOLUTION/DROPS;OPHTHALMIC	207795-001	Nov 2, 2017
Bausch And Lomb	VYZULTA	latanoprostene bunod	SOLUTION/DROPS;OPHTHALMIC	207795-001	Nov 2, 2017
Bausch And Lomb	VYZULTA	latanoprostene bunod	SOLUTION/DROPS;OPHTHALMIC	207795-001	Nov 2, 2017

International Patents for VYZULTA

When does loss-of-exclusivity occur for VYZULTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Intellectual Property Organization (OAPI)

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VYZULTA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2292836	COMPOSITIONS PHARMACEUTIQUE DE PROSTAGLANDINES (PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS)
Hong Kong	1096084	PROSTAGLANDIN NITROOXYDERIVATIVES
Denmark	1704141
Mexico	PA06007678	NITROXIDERIVADOS DE PROSTAGLANDINAS. (PROSTAGLANDIN NITROOXYDERIVATIVES.)
Ukraine	84726	ПРОИЗВОДНЫЕ ПРОСТАГЛАНДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ) И СПОСОБ ЛЕЧЕНИЯ ГЛАУКОМЫ ИЛИ ГИПЕРТЕНЗИИ ГЛАЗА;ПОХІДНІ ПРОСТАГЛАНДИНІВ, СПОСІБ ЇХ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ ГЛАУКОМИ АБО ГІПЕРТЕНЗІЇ ОКА (PROSTAGLANDIN DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION (VARIANTS) AND METHOD FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION)

Market Dynamics and Financial Trajectory for VYZULTA (Netarsudil Ophthalmic Solution)

Last updated: December 28, 2025

Executive Summary

VYZULTA (netarsudil ophthalmic solution) is a novel glaucoma and ocular hypertension medication developed by Aerie Pharmaceuticals. Approved by the FDA in December 2017, VYZULTA has carved out a niche within the intraocular pressure (IOP) lowering therapies segment. This report analyzes the current market landscape, growth drivers, competitive positioning, regulatory conditions, and future financial trajectories for VYZULTA.

Introduction

Glaucoma, a leading cause of irreversible blindness, afflicts an estimated 76 million globally, projected to reach 111 million by 2040 [1]. Elevated intraocular pressure (IOP) remains a primary modifiable risk factor. The global glaucoma therapeutics market is expected to reach USD 7.55 billion by 2027, growing at a CAGR of 4.5% [2]. VYZULTA, as a selective Rho kinase (ROCK) and norepinephrine transporter inhibitor, offers a novel mechanism, increasing its strategic importance.

This analysis assesses market dynamics—patient demands, regulatory influences, competitive landscape—and projects the drug's financial trajectory over the next five years.

---

What Are the Key Market Drivers for VYZULTA?

1. Rising Glaucoma Prevalence and Aging Population

• The aging demographic accelerates glaucoma incidence.
• Predicted increase in prevalence by nearly 50% in the next two decades [1].
• Greater unmet needs for novel, effective therapies.

2. Limitations of Existing Treatments

• First-line treatments like prostaglandin analogs (e.g., Latanoprost) are efficacious but associated with ocular side effects.
• Patients often require combination therapies, increasing complexity and costs.
• VYZULTA's distinct mechanism offers an alternative for patients intolerant to traditional agents.

3. Favorable Efficacy and Safety Profile

• Clinical trials demonstrated a significant IOP reduction (mean of 3.3 mm Hg vs. 1.4 mm Hg placebo at 3 months) [3].
• Once-daily dosing enhances compliance.
• Generally well-tolerated with manageable side effects, mainly conjunctival hyperemia.

4. Increasing Awareness and Physician Adoption

• Growing clinical familiarity through key opinion leader (KOL) engagement.
• Institutional endorsements and payer coverage expansion.

---

How Does the Regulatory Landscape Affect VYZULTA?

FDA Approval and Indications

• Approved for open-angle glaucoma and ocular hypertension.
• Labeling emphasizes adjunctive use—but monotherapy potential is under investigation.

Global Regulatory Outlook

• Currently limited to the US.
• Submissions underway or planned for Europe and Asia (e.g., Japan, China).
• Potential expirations of patent exclusivity in mid-2030s could introduce biosimilar or generic competition.

Reimbursement Policies

• Reimbursement challenges are typical for ophthalmic drugs; payers demand demonstration of cost-effectiveness.
• VYZULTA’s pricing (~USD 350-400 per month) fits within typical glaucoma treatment costs but remains an obstacle in budget-constrained healthcare systems.

---

Who Are the Main Competitors and How Do They Position Against VYZULTA?

Drug	Mechanism	Market Segment	Status	Strengths	Weaknesses
Latanoprost (Xalatan)	Prostanoid (FP receptor agonist)	First-line therapy	Established, OTC availability	Proven efficacy, low dosing frequency	Side effects, pigment changes
Timolol (Timoptic)	Beta-blocker	First-line therapy	Established	Cost-effective, extensive data	Systemic side effects, contraindications
Netarsudil (VYZULTA)	ROCK inhibitor; NE transporter	Adjunct or monotherapy	Approved (2017), expanding use	Unique MOA, rapid IOP reduction	Conjunctival hyperemia, tolerability concerns
Brimonidine (Alphagan)	Alpha-2 adrenergic agonist	Adjunct therapy	Established	Additional IOP lowering	Allergic conjunctivitis
Ripasudil (Japan)	ROCK inhibitor	Regional (Japan)	Approved in Japan	Similar MOA to VYZULTA	Limited global presence

VYZULTA’s key differentiation lies in its dual ROCK and norepinephrine transporter inhibition, providing improved IOP reduction compared to some competitors, especially in patients with inadequate response to prostaglandins.

---

What Is the Projected Financial Trajectory of VYZULTA?

Historical Sales Data (2020–2022)

Year	Estimated Sales (USD millions)	Key Market Penetration Metrics
2020	50	Launched in late 2017, initial adoption growth
2021	120	Increased physician awareness, expanded indications
2022	200	Rising prescriptions, payer coverage broadened

Forecasted Revenue Growth (2023–2027)

Year	Estimated Sales (USD millions)	Assumptions
2023	300	Greater geographic expansion, increased market share
2024	400	Adoption in hospital and primary care settings
2025	520	Additional formulary approvals, increased patient pool
2026	650	Entry into more regional markets, monotherapy approval
2027	800	Consolidation, competitor patents expiring

Drivers of Growth

• Increased physician awareness and guideline inclusion.
• Expanded geographic markets, notably Europe and Asia.
• Combination therapy potential with existing agents.
• Price optimization strategies and competitive positioning.

Risks and Constraints

• Patent expiration in mid-2030s may invite biosimilar competition.
• Regulatory delays in key markets.
• Slow uptake due to cost or clinician resistance.
• Emergence of superior alternatives.

---

How Will Market and Policy Changes Influence VYZULTA?

1. Pricing and Reimbursement Policies
   Price negotiations and value-based care models may constrain margins but also open opportunities for formulary inclusion [4].

2. Healthcare System Evolution
   Shift towards early intervention and telemedicine models could accelerate adoption.

3. Regulatory Approvals
   Fast track and orphan drug designations may facilitate market entry in emerging jurisdictions.

4. Competitive Innovations
   Development of next-generation ROCK inhibitors or gene therapies could challenge VYZULTA’s market share.

---

What Are the Opportunities and Challenges Ahead?

Opportunities

• Broadening indications to include prophylactic use.
• Developing fixed-dose combination formulations.
• Partnering with global health initiatives to expand access.
• Leveraging real-world evidence to support reimbursement.

Challenges

• Navigating competitive landscapes with entrenched therapies.
• Managing safety profile concerns, notably conjunctival hyperemia.
• Price sensitivity in developing countries.
• Patent expiry risks leading to biosimilar proliferation.

---

Conclusion: The Financial Outlook for VYZULTA

Based on current trends, VYZULTA is positioned favorably within the glaucoma med-therapeutic landscape. Its innovative MOA and favorable efficacy profile support sustained revenue growth, potentially reaching USD 800 million globally by 2027. Strategic expansion into key markets, combined with ongoing clinical research to broaden indications and improve tolerability, will be critical.

However, commercialization success will depend on the ability to navigate pricing pressures, competitive responses, and regulatory hurdles. Early investments in key opinion leader engagement and payer negotiations will complement the growing clinical evidence base, ensuring VYZULTA’s financial trajectory remains positive.

---

Key Takeaways

• VYZULTA capitalizes on unmet needs for effective, once-daily IOP lowering therapies, benefiting from its novel mechanism.
• The global glaucoma market’s expansion, driven by demographic shifts, underpins future growth prospects.
• Regulatory efforts and geographic expansion will be pivotal to reaching projected sales figures.
• Competition from established therapies and biosimilars pose significant challenges.
• Strategic partnerships, formulary placements, and cost-effectiveness demonstrations are vital for sustained financial success.

---

FAQs

Q1: What distinguishes VYZULTA from other glaucoma medications?

A1: VYZULTA’s dual mechanism as a ROCK inhibitor and norepinephrine transporter blocker offers a novel, potent IOP reduction with once-daily dosing, differing from prostaglandins and beta-blockers.

Q2: When is VYZULTA expected to face generic competition?

A2: Patent protection extends into mid-2030s; generic biosimilars may emerge post-expiry, impacting pricing and market share.

Q3: Are there ongoing trials to expand VYZULTA’s indications?

A3: Yes. Clinical trials exploring monotherapy efficacy and potential prophylactic use are underway, which could further boost market penetration.

Q4: Which regions represent the highest growth opportunities?

A4: Europe and Asia Pacific, especially China and Japan, offer significant potential due to population size and increasing glaucoma awareness.

Q5: How does VYZULTA’s safety profile influence its market acceptance?

A5: While generally well-tolerated, common side effects like conjunctival hyperemia may limit use in some patients; ongoing post-marketing surveillance aims to optimize safety management.

---

References

1. Tham YC, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology. 2014;121(11):2081–2090.
2. Grandview Research. Glaucoma Therapeutics Market Size & Trends. 2022.
3. Aerie Pharmaceuticals. VYZULTA (netarsudil ophthalmic solution) Highlights of Prescribing Information. 2017.
4. IQVIA. Value-Based Pricing and Reimbursement Trends. 2021.

---

Note: All sales figures and projections are estimative and hypothetical, based on available industry trends and market data.